Personalized cancer vaccines
US12295976B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Mar 28, 2019 |
| Grant date | May 13, 2025 |
| Priority date | — |
| Expiry date | Jun 9, 2042 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides for a recombinant adenoviral vector comprising a recombinant oncolytic adenovirus which has: (1) a modified transcription regulatory sequence wherein the adenoviral vector is transcriptionally active in cancer cells and/or hyperproliferative cells and transcriptionally attenuated in normal cells, and (2) a transgene encoding one or more cancer antigens that are specific to a subject. The invention further provides a method of producing said recombinant adenoviral vector. The recombinant oncolytic adenoviral vector described above is used in methods of stimulating a heightened immune response against a cancer antigen in a subject or a method of treating cancer in a subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.